Table 3.
Classification and incidence of acute and late urinary toxicity after the end of combined treatment (HDR and hEBRT)
| Acute Toxicity (by 3 months), Grade | Late (by 12 months) Grade | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Toxicity (%) | 1 | 2 | 3 | 1 | 2 | 3 | ||||||
| Cystitis | 4 | 10.2% | 2 | 5.1% | 0 | 2 | 5.1% | 0 | 0 | |||
| Urinary frequency | 2 | 5.1% | 3 | 7.7% | 0 | 4 | 10.2% | 2 | 5.1% | 0 | ||
| Hematuria | 0 | 0 | 1 | 2.6% | 0 | 0 | 0 | |||||
| Pain | 0 | 0 | 1 | 2.6% | 0 | 0 | 0 | |||||
| Slow stream | 0 | 2 | 5.1% | 0 | 0 | 0 | 1 | 2.6% | ||||
| Total | 6 | 15.4% | 7 | 17.5% | 2 | 5.1% | 6 | 15.4% | 2 | 5.1% | 1 | 2.6% |
HDR: high dose rate brachytherapy; hEBRT: hypofractionate external beam radiotherapy